Humabs Biomed, Subsidiary Of Vir Biotechnology

Humabs BioMed, a Subsidiary of Vir Biotechnology Inc., is a leading Swiss antibody therapeutics company that discovers and develops superior monoclonal antibodies directly derived from individuals whose immune system has successfully responded to major diseases. The company currently focuses on infectious diseases, but also has selected antibodies against inflammatory diseases and cancer in the pipeline. Please note: Humabs BioMed SA is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir Biotechnology, Inc’s recruiting process here: https://bit.ly/3ZGcmke.